# Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

> **NCT06926634** · PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 32 (estimated)

## Conditions studied

- High Grade Neuroendocrine Neoplasms

## Interventions

- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT06926634
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-09
- **Primary completion:** 2034-12-31
- **Final completion:** 2034-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926634, "Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06926634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*